To identify rate-limiting steps in T cell-independent type 2 antibody production against polysaccharide antigens, we performed a genome-wide screen by immunizing several hundred pedigrees of C57BL/6 mice segregating N-ethyl-N-nitrosurea-induced mis-sense mutations. Two independent mutations, Tilcara and Untied, were isolated that semi-dominantly diminished antibody against polysaccharide but not protein antigens. Both mutations resulted from single-amino-acid substitutions within the kinase domain of protein kinase C-b (PKCb). In Tilcara, a Ser5524Pro mutation occurred in helix G, in close proximity to a docking site for the inhibitory N-terminal pseudosubstrate domain of the enzyme, resulting in almost complete loss of active, autophosphorylated PKCbI, whereas the amount of alternatively spliced PKCbII protein was not markedly reduced. Circulating B cell subsets were normal and acute responses to B-cell receptor stimulation such as CD25 induction and initiation of DNA synthesis were only measurably diminished in Tilcara homozygotes, whereas the fraction of cells that had divided multiple times was decreased to an intermediate degree in heterozygotes. These results, coupled with evidence of numerous mis-sense PRKCB mutations in the human genome, identify Prkcb as a genetically sensitive step likely to contribute substantially to population variability in anti-polysaccharide antibody levels.
INTRODUCTION
A hallmark of the adaptive immune system is the production of antibodies by B cells targeting varying types of antigens. Genetic studies in mice have distinguished different routes for antibody production depending on the nature of the antigen. First, antigens have been classified as eliciting either T cell-dependent or T cellindependent (TI) responses based on the ability to induce antibodies to a given antigen in athymic nude mice. 1 Antigens that elicit TI antibody responses have been further sub-divided into TI-1 or TI-2 antigens based on their ability to stimulate responses in the X-linked immunodeficiency (Xid) mouse strain, which has a crippling Btk mutation that affects some intracellular signals elicited by antigen binding to the B-cell antigen receptors (BCRs). Xid mice are capable of making antibodies against TI-1 antigens, such as bacterial lipopolysaccharide (LPS) or flagellin, because these signal B-cell proliferation through Toll-like receptors (TLRs). 2 By contrast, Xid mice fail to make antibodies to TI-2 antigens such as the polysaccharide envelopes of some bacteria or synthetic polysaccharides such as Ficoll, because these antigens signal B-cell proliferation by extensively cross-linking the BCR into large aggregates that persist on the cell surface. 1, 3, 4 TI-2 responses are mediated primarily by the secretion of short-lived IgM isotype antibodies by marginal zone (MZ) B cells in the spleen 5 and the B-1 cells in the serous cavities. 6, 7 In a TI antibody response, the stimulation of the BCR leads to the phosphorylation of immunoreceptor tyrosine-based activation motifs in the cytoplasmic tails of the signal transducing molecules CD79a (Iga) and CD79b (Igb). This allows the phosphorylation of multiple signalling kinases such as Bruton's tyrosine kinase (BTK) and the phospholipase c g-2 (PLCg2)-mediated elevation of intracellular calcium. These kinases activate protein kinase C-b (PKCb), which starts a phosphorylation cascade activating the Card11/Malt1/Bcl-10 complex. This results in the recruitment of the nuclear factor-kB transcription factor to inducible genes that stimulate B-cell proliferation and TI-2 antibody production.
Defects in TI-2 antibody responses result in increased susceptibility to encapsulated bacterial infections such as Haemophilus influenza type b, Neisseria meningitides and Streptococcus pneumoniae. 8 These infections severely impact on young children particularly in the developing world. Chronic infection and poor disease management can lead to mortality. Lower antibody production against these antigens is correlated with recurrent infection [9] [10] [11] but the underlying basis for population variation is not known. Further understanding of the underlying genetic alterations that make individuals more susceptible to these diseases are important for the identification of therapeutic targets for the disease and to enhance vaccination and immunization strategies.
A unique feature of modern humans is the massive degree of population expansion that has occurred in the last several hundred generations. Deep sequencing efforts have recently revealed that this growth has resulted in an equally massive increase in the frequency of heterozygous deleterious mutations [12] [13] [14] [15] [16] with each person carrying on average 100 deleterious mutations in the genome with approximately 20 being complete loss of function variants. 17 Each of these mutations are individually too recently arising and rare in the population at large to have yet been removed by purifying selection, yet cumulatively they amount to a large genetic burden. Rare variants account for 95% of the protein-altering mutations predicted to be deleterious in the current generation of humans, and account for B25% of the deleterious mutations in any individual's genome. Based on the de-novo mutation rate in human reproduction (1.4 Â 10 À 8 per bp), the current generation of humans is now large enough (6 Â 10 9 individuals) to saturate every nucleotide of the genome with de-novo mutations. 12 Among this burden of recent mutations will be many unique heterozygous mutations in the large network of genes that control antibody production. Heterozygous mutations that affect rate-limiting steps in antibody production will account for a substantial amount of inherited variability in antibody formation, but no systematic efforts have yet been made to identify these rate-limiting steps.
In this study, we have taken an experimental approach in mice to evaluate the impact of increasing the genome-wide burden of rare variants on TI-2 antibody formation against polysaccharide antigens. We used N-ethyl-N-nitrosurea (ENU) mutagenesis of inbred C57BL/6 mice to increase the frequency of singlenucleotide variants, coupled with systematic screening for variability in the antibody response following immunization with a haptenated polysaccharide, NP (4-hydroxy-3-nitrophenylacetyl)-Ficoll. 18 Two semi-dominant mutations were isolated causing selective deficits in TI-2 antibody response, and both were due substitutions in conserved residues in the catalytic domain of PKCb (Prkcb). These results identify PRKCB as a rate-limiting point in the network of genes controlling TI-2 antibody, and provide novel animal models to analyze the biochemistry of the two PKCb enzyme isoforms.
RESULTS
Generation of the Tilcara and Untied mutant mice and identification of the causative mutation in Prkcb A genetic screen was performed to identify genes that are critical for TI antibody production. First generation offspring (G 1 ) from ENU-treated inbred C57BL/6 male mice were used as founders for separate inbreeding pedigrees by breeding with wild-type females, and subsequently intercrossing their G 2 progeny to generate a G 3 generation. Twelve-week-old G 3 offspring from 130 pedigrees were screened by immunization with a panel of antigens that differentially elicit TI and T-dependent antibody responses. T cell-dependent antibody response were measured by immunizing each G 3 animal with alum-precipitated chicken g-globulin coupled to hapten arsonate (ABA-CGG) and heat killed Bordetella pertussis (BP). After 5 weeks, the mice were re-immunized with ABA-CGG to test T cell-dependent memory and affinity maturation, and immunized at the same time with NP-Ficoll, which elicits a T cell-independent type 2 (TI-2) antibody response. 18, 19 Three of five mice tested in the Tilcara pedigree exhibited lower TI-2 responses compared with littermate counterparts (Figures 1a and b ), but had normal T-dependent responses indicating that these mice have no general problem in the generation of specific antibodies.
To link the mutation responsible for low TI-2 antibody to a single chromosome, an F 2 intercross was performed between offspring from an affected C57BL/6 (B6) G 3 mouse and a wild-type C57BL/10 (B10) mouse. Immunization of the F 2 offspring with NP-Ficoll identified three groups of animals. The first group had a very low TI-2 antibody response ('affected'), a second group had normal levels of antibodies ('unaffected') and a third group showed an intermediate response. Pooled DNA samples from affected and unaffected mice were tested using a panel of single-nucleotide polymorphisms between the B6 and B10 strains, linking the Tilcara trait to chromosome 7 distal to singlenucleotide polymorphism rs1347954 at 109 Mb. Because of the semi-dominant inheritance the location of the mutation was further refined by immunizing offspring from a cross between (C57BL/6 Â CBA)F 1 animals with an intermediate response and wild-type B6 mice. Genotyping of intermediate responders and unaffected animals localized the mutation to an 8.3 Mb interval ( Figure 1c ) containing 199 predicted genes, including 16 genes with known immunological function. Three of these, Cd19, Cd11b and Prkcb, were selected as candidate genes for sequencing of splenic mRNA, revealing a single T-to-C point coding sequence mutation in Prkcb at base pair 1654 ( Figure 1d ).
A second screen of another cohort of ENU mutagenized mice revealed another mouse strain, Untied, that also displayed a semidominant defect in IgM antibody selectively against TI-2 antigens ( Figure 1e ). Sequencing of Prkcb revealed an independent mutation in this strain: in this case a T to C transition at position 1469 of the Prkcb transcript. The Tilcara and Untied mutations both result in single-amino-acid substitutions of highly conserved residues in the PKCb kinase domain. Untied results from a tyrosine to histidine substitution at amino acid 417. This alters a residue that is absolutely conserved from mammals to invertebrates, in the middle of b-sheet 5 near the conserved gatekeeper residue (Met420) that controls access to the ATP-binding pocket (Figure 1f -h). In Tilcara, Ser552 in the middle of a-helix G on the C-lobe of the kinase domain, on the lower lip of the substratebinding cleft (Figure 1f -h), is mutated to a proline that would be predicted to break the helical structure. The mutated S552 is absolutely conserved from mammals to fish and highly conserved between different murine PKC family members ( Figure 1i ). The genetic evidence that these are causal is thus supported by three independent mutations, since a comparable semi-dominant loss of TI2 antibody responses was also observed in Prkcb knockout mice. 20 Two isoforms of PKCb, PKCbI and PKCbII, are produced in mice, humans and other mammals by alternative mRNA splicing of exons encoding PKCbI residues 622-671 (622-673 in PKCbII). Hence, the S552P Tilcara mutation affects the part of the protein that is common to both isoforms. Western blotting with antibodies specific for one or other isoform revealed a consistent reduction in the PKCbI isoform in purified B-cell lysates from Prkcb til/til mice compared with wild-type controls, whereas Tilcara heterozygous mice had intermediate protein expression (Figure 2a ). By contrast, there was no consistent decrease in the PKCbII isoform ( Figure 2a ).
Following translation, both PKCbI and PKCbII undergo sequential phosphorylation at threonine and serine residues to become catalytically active, and these modifications can be revealed indirectly by slower mobility in SDS-polyacrylamide gel electrophoresis and directly by phospho-specific antibodies. 21 When the mutant or wild-type PKCbI isoform was expressed in 293T cells, the Tilcara S552P mutation caused almost complete absence of the slower migrating PKCbI form, although the more rapidly migrating species was present at comparable levels in soluble cytoplasmic component of the NP-40 lysed-transfected with mutant or wild-type vectors (Figure 2b ). The S552P mutation had a similar effect when the PKCbII isoform was expressed in transfected 293T cells, although a small amount of slowly migrating protein was present in this case. The first posttranslational modification step in the maturation of PKCbI and II, involving Thr500 phosphorylation in the kinase domain activation loop by phosphoinositide-dependent kinase-1, 22 was tested by western blotting B-cell lysates with an antibody to phospho-T500 ( Figure 2c ). Comparable amounts of phospho-T500 PKCb were present in wild-type, heterozygous and Prkcb til/til B cell lysates. This activation loop phosphorylation in turn allows PKCbI to auto- phosphorylate T642 in the turn motif and S660 in the hydrophobic motif of the alternatively spliced C-terminal tail, releasing the fully active enzyme into the cytosol. 23 Western blotting with phospho-T642 PKCbI antibody revealed a profound decrease in autophophorylated protein in B cells from homozygous Prkcb til/til mutant mice and an intermediate deficit in heterozygotes ( Figure 2d ). Thus, the S552P mutation almost completely eliminates the fully active species of PKCbI in B cells, establishing that the Prkcb til/til mutation diminishes PKCb function both in situ in primary B cells and when the mutant protein is expressed on its own in a heterologous cell line.
Diminished basal serum IgM and IgG3 and TI antibody responses in Tilcara mouse
The semi-dominant biochemical effects of the Tilcara S552P PKCb mutation defined above were accompanied by semi-dominant effects on antibody production to the TI-2 antigen, NP-Ficoll ( Figure 3a ). When NP-specific IgM and IgG3 were measured in a large cohort of animals 7 days post immunization, Tilcara heterozygous mice made significantly less antibody than wild-type controls, whereas Prkcb til/til homozygotes made lower responses than heterozygotes. Likewise, in unimmunized age-matched mice there was a semi-dominant decrease in natural serum IgM antibody (Figure 3b ), which decreased B50% and B75% in Tilcara heterozygous and homozygous mice, respectively, compared with wild-type controls. Basal serum IgG3 was also decreased B75% in Tilcara heterozygous and homozygous mice.
Serum IgG1 and total IgG were nevertheless comparable between mutant and wild-type animals ( Figure 3b ). Likewise, there were normal T cell-dependent antibody responses following immunization with ABA-CGG and heat killed BP, which depend on T H 2 and T H 1 cells to elicit CGG-specific IgG1 and BP-specific IgG2c response. 24 There were no significant differences in these antibody responses between wild-type mice and Tilcara heterozygous or homozygous animals ( Figure 3c ). The S552P mutation in Prkcb thus causes a selective defect in TI antibody responses.
Lymphocyte development and decreased B-1a cells in Tilcara mouse B lymphocyte development and peripheral subsets were assessed in Tilcara mice by flow cytometry, with particular focus on B cells that are responsible for TI-2 antibody responses-MZ and B-1 cells. In the bone marrow, no significant differences in percentages of early pro-B/pre-B (B220 lo IgM lo ), immature (B220 lo IgM hi ) and mature (B220 hi IgM hi ) B cells could be detected between wildtype, Prkcb wt/til , Prkcb til/ti mice (Figure 4a ). Similarly, there was no discernable effect of the mutation on transitional 1 (CD93 hi IgM lo CD23 lo ), transitional 2 (CD93 hi IgM hi CD23 hi ), transitional 3 (CD93 hi IgM lo CD23 hi ), follicular (CD93 lo CD23 hi CD21 int ) and MZ (CD93 lo CD23 lo CD21 int ) B-cell subpopulations in the spleen (Figure 4b ). Cell surface IgM was downregulated normally during maturation of follicular B cells in Tilcara homozygotes: a result that stands in contrast to mutations in BTK 25 or PLCg2 26 immediately upstream of PKCb or with mutations in CARD11 27 immediately downstream, which cause surface IgM to remain high on follicular B cells. T-cell subsets in the thymus, lymph nodes and spleen were also comparable (data not shown). The only striking abnormality in lymphocyte development was in the peritoneal cavity, where CD11b hi IgM hi B-1 cells were markedly decreased in frequency selectively in Prkcb til/til homozygous mice compared with wild-type and Prkcb wt/til heterozygotes (Figure 4c ). Subdivision of the B-1 cells into CD5 þ B-1a and CD5 -B-1b subpopulation revealed that this difference was attributed largely to the near absence of the B-1a population in homozygous mutant animals ( Figure 4c ).
Competitive mixed bone marrow chimeras were produced by transplanting irradiated mice with equal amounts of bone marrow from CD45.1 wild-type and CD45.2 Prkcb til/til donors. Analysis of the reconstituted chimeric animals showed that the Prkcb til/til mutation did not affect the numbers of B-and T-cell subsets in central and peripheral lymphoid tissue, which were drawn equally from mutant and wild-type lymphocytes. By contrast, peritoneal B-1a cells and to a lesser extend MZ cells were preferentially derived from the wild-type lymphocytes and not from those harboring the Prkcb til/til mutation, demonstrating an intrinsic, cellautonomous requirement for fully active PKCb selectively in the formation of B1 B cells (Supplementary Table1 and Supplementary  Figure 1 ). Recessive deficits in the acute BCR response We next analyzed the consequences of the S552P Prkcb til mutation on B-cell responses to receptor stimulation in vitro. Increased intracellular calcium after BCR stimulation was monitored using the calcium-sensing dye, Indo-1, in co-cultured CD45.1 wild-type and CD45.2 Prkcb til/til cells stimulated with sub-optimal and optimal concentrations of anti-IgM antibody (Figure 5a ). By overlaying the paired responses from mutant and wild-type cells stimulated together, there was no discernable difference in the intracellular calcium response between wild-type and Prkcb til/til cells. Thus, the early steps in BCR signalling leading to PLCg activation, which lies immediately upstream of PKCb, appeared unaffected by the Prkcb til mutation.
BCR, CD40 or TLR signalling induces an early wave of gene transcription in B cells that includes the cell surface protein CD25. CD25 induction by the BCR but not CD40 or TLR4 is compromised in B cells with mutations in Card11, 27 a known immediate substrate of PKCb. 28, 29 Flow cytometric analysis showed that CD25 was induced by anti-IgM stimulation of wild-type B cells but poorly induced in homozygous mutant Prkcb til/til B cells stimulated in the same culture (Figures 5b and c) . By contrast, CD25 was induced equivalently in mutant and wild-type B cells stimulated with 1 mg ml À 1 IgM þ 10 mg ml À 1 CD40L or the TLR4 agonist, LPS. Unlike the homozygous mutant B cells, Tilcara heterozygous B cells exhibited no discernable decrease in CD25 induction following anti-IgM stimulation (Figures 5b and c) .
Entry of B cells into cell cycle was measured by incorporation of radioactive thymidine after 2 days in culture. Spleen cells from individual homozygous Prkcb til/til mice had markedly diminished thymidine incorporation in response to BCR stimulation, whereas their response to LPS (TLR4), CpG (TLR9) or antibody to CD3 was normal (Figures 6a-d ). Heterozygous Prkcb til/ þ B cells did not have significantly reduced DNA incorporation upon anti-IgM stimulation. The combination of anti-IgM and anti-CD40 stimulation partially restored the initiation of proliferation in Prkcb til/til cells (Figure 6e ). Measurement of B-cell division by dilution of the intracellular dye carboxyfluorescein-succinimidyl-ester (CFSE) yielded similar results and enabled cell autonomous effects of the Prkcb mutation to be confirmed by comparing CFSE dilution in cocultured CD45.1 normal B cells 5 days post stimulation. Few homozygous mutant B cells had divided multiple times in response to anti-IgM, whereas the percentage of divided Tilcara heterozygous B cells was significantly lower than in wild-type controls (Figures 6f  and g) . Stimulation with anti-IgM and CD40 greatly enhanced the fraction of wild-type B cells that had divided multiple times, but only modestly increased the response of homozygous mutant B cells, whereas the response of heterozygous mutant B cells was clearly intermediate. Collectively, these results indicate that the semidominant effects of Prkcb mutation on BCR-induced proliferation are difficult to discern during the entry into cycle but become more apparent when measured after several cell divisions. This may reflect either less re-initiation of subsequent cell divisions in heterozygous mutants or diminished survival of their divided progeny compared with the wild-type B cells in the same culture.
DISCUSSION
The results above represent a genome-wide experimental approach to identify rate-limiting steps in TI-2 antibody production that are particularly sensitive to heterozygous mis-sense mutations. Two independent, semi-dominant mutations were revealed, Tilcara and Untied, both changing individual amino acids within the catalytic domain of PKCb. Semi-dominant loss of TI-2 antibody was also reported in Prkcb knockout mice. 20 The findings identify Prkcb as a key genetic node with a gene-dosage sensitive role selectively in BCR-induced cell division and TI-2 antibody responses. In contrast with these semi-dominant effects on TI-2 antibody responses, formation of B1a B cells in the peritoneal cavity and basal production of serum IgM and IgG3 were only diminished in Tilcara homozygous mutants. Likewise, early responses to BCR stimulation such as CD25 induction and initiation of DNA synthesis were only measurably diminished in homozygotes, whereas the fraction of cells that had divided multiple times was decreased to an intermediate degree in heterozygotes.
In Tilcara, the Ser 552 4Pro mutation differential affected the alternatively spliced PKCbI and PKCbII isoforms. The active, autophosphorylated PKCbI species were preferentially diminished and the overall amount of PKCbI protein was greatly decreased in homozygotes and markedly decreased in heterozygotes, whereas the overall amount of PKCbII protein was not markedly reduced. More complete loss of autophosphorylated PKCbI than PKCbII was also observed when tagged versions of the proteins were transiently expressed in 293 cells. Preferential loss of autophosphorylated PKCbI has several possible explanations. Ser 552 lies in helix G of the catalytic domain, which forms a lower lip on the catalytic site and contains a series of acidic residues, EDE-DELFQS 552 , that interact with basic Arg or Lys residues in the pseudosubstrate inhibitory domain that lies at the PKCb N-terminus. [30] [31] [32] Serine 552 is absolutely conserved in vertebrates, and its substitution by proline would be predicted to break the ahelical structure and diminish binding to the pseudosubstrate inhibitory domain and to kinase substrates. Decreased substrate binding may diminish autophosphorylation to generate the fully active species, whereas decreased binding to the pseudosubstrate domain may accelerate dephosphorylation and degradation of the kinase. When the pseudosubstrate domain is allosterically dislodged from helix G upon PKCb binding to membrane lipids, this opening up is rapidly followed by dephosphorylation of the kinase and, in the case of PKCbI, rapid protein degradation. 33 By contrast, PKCbII degradation after dephosphorylation occurs more slowly, and this may explain the selective loss of PKCbI in Tilcara B cells.
The resulting semi-dominant immunological effects of the Tilcara mutation favor the view that catalytically active PKCbI is the critical enzyme isoform for progressive B-cell division in response to BCR cross-linking and for TI-2 antibody formation. This genetic inference is supported by biochemical evidence that PKCbI preferentially associates with other essential proteins for BCR-induced nuclear factor-kB signalling and proliferation, in particular BTK and CARD11. 29, 34 The immune phenotype of Tilcara homozygotes had a number of significant differences compared with knockout mice that completely lack both PKCb isoforms. PKCb-null mice had defects in both TI-2 and T-dependent (TD) antibody responses, 20 whereas Tilcara homozygous mice had low TI-2 antibody responses but normal TD antibody responses. PKCb-null mice also had fewer mature IgM lo IgD hi follicular B cells in the spleen 35 and fewer mature follicular B cells that had recirculated to the bone marrow, 36 whereas the numbers of both subsets were normal in Tilcara homozygotes. There are two plausible explanations for the different phenotypes. First, the Prkcb til/til mutation may result in the expression of small amounts of catalytically competent PKCbI kinase with residual activity. This activity may be insufficient for the stimulation of TI-2 antibody responses but sufficient for TD responses and mature B-cell survival. TI-2 antibody responses are highly dependent on BCR cross-linking and stimulation via the BCR receptor. 8 In contrast, the TD antibody response involves other mitogenic signals such as CD40 ligand, 37 which may activate complementary signalling pathways and kinases that counteract the partial defect in PKCbI kinase activity. This hypothesis is also supported by the observation that addition of CD40L to the anti-IgM stimulation was able to normalize upregulation of CD25 and helped at least partially to overcome the defective proliferation in response to anti-IgM alone. Alternatively, there may be a division of labor between the PKCbI and PKCbII isoforms, where the PKCbI isoform is involved in TI-2 antibody response, whereas the PKCbII isoform that was less compromised in Tilcara is involved in TD antibody production and mature B-cell survival. Support for this possibility comes from the observation that PKCbI and PKCbII have different roles in the insulin receptor signalling pathway. 38 It would be interesting in future studies to engineer mice that selectively lack PKCbI protein entirely while retaining normal PKCbII.
Heterozygous mis-sense mutations, like those in Tilcara and Untied, have accumulated in the current human population at a massive scale, because of exponential population growth and outbreeding. [12] [13] [14] [15] [16] Whereas offspring of ENU-mutagenized mice inherit B40 novel mis-sense variants, a 'normal' current human genome inherits more than 5000 mis-sense variants including 300-600 that are predicted to be deleterious to protein function and 75-150 that represent rare, recent deleterious mutations yet to be subject to purifying selection. 16 Hence, the finding of two heterozygous missense Prkcb mutations that reduce TI-2 antibody responses among several hundred ENU mouse pedigrees can be extrapolated to predict at least a similar B1% frequency in human families. Indeed, recent exome sequence data from 2440 individuals 16 annotates 21 independent mis-sense mutations in PRKCB including many in the kinase domain (http:// evs.gs.washington.edu/EVS/). It will be important to test if PRKCB is equally gene-dosage sensitive in human B cells. Extrapolating from the mouse experiments here, and from evidence that B20% of missense mutations are profoundly crippling, 39 of the 1% of people carrying unique PRKCB variants at least 20% of these individuals (0.2% of the population) would be expected to make less antibody to polysaccharide antigens of enveloped bacteria but exhibit normal circulating B-cell subsets, serum IgG, TD antibody to tetanus toxoid and measles, mumps and rubella vaccination. One could readily envisage additive or epistatic interactions between heterozygous mutations in PRKCB and in other rate-limiting genes for BCR-induced proliferation, as we have shown occurs between heterozygous mutations in Lyn, Cd22 and Ptpn6 encoding interacting negative regulators of BCR signalling. 40 These experimental results, coupled with human exome sequencing, thus open up a new way to analyze variability in humoral immunity in the wider population, among individuals who would not be defined as having a primary immunodeficiency.
MATERIALS AND METHODS ENU treatment of mice
Male C57BL/6 mice aged 8-to 15-week old were treated with three doses of 100 mg kg À 1 ENU (Sigma, Sydney, NSW, Australia) prepared in 10% ethanol, citrate buffer (pH5.0), 1 week apart, as previously described. 41 The mice were housed in specific pathogen-free conditions at the Australian National University Bioscience Facility or the Scripps Research Institute vivarium. All animal procedures were approved by the Australian National University Animal Ethics and Experimentation Committee or the Institutional Animal Care and Use Committee of the Scripps Research Institute.
Immunization and ELISA
Mice were immunized by intraperitoneal injections. For TI-2 immune response, the mice received 25 mg of NP-Ficoll (Biosearch Technology, Novato, CA, USA) in sterile phosphate-buffered saline. For TD responses, mice received 50 mg of CGG with hapten arsonate (Biosearch Technology) and 5 Â 10 8 whole killed BP (Lee Labs, Becton Dickinson, Grayson, GA, USA). Total and antigen-specific antibodies in serially diluted sera were detected by ELISA on Maxisord plates coated with CGG, sonicated B. pertussis or NP-Ficoll. Bound antibodies were detected with alkaline phosphate antibodies to specific mouse isotypes using the phosphatase substrate system. Plates were read at 405-650 nm using a Thermomax microplate reader (Molecular Devices, Sunnyvale, CA, USA). The titres for serum samples were calculated as the difference of serum concentrations required to achieve 50% maximum optical density compared with a standard control ran on each plate.
Typing of mutation
Candidate mRNAs were amplified in 300-800 bp fragments using PCRs from spleen complementary DNA and resequenced by the Biomolecular Resource Facility (JCSMR, ANU) using the ABI 3730 capillary sequencer and analyzed using the 
Bone marrow chimeras
All recipients were sub-lethally irradiated with two doses of 450 rads and reconstituted via intravenous injections with 2 Â 10 6 bone marrow cells. .2% for Prkcb wt/til (n ¼ 5) and Prkcb til/til (n ¼ 5), respectively; for 10 mg ml À 1 anti-IgM: 66.6 ± 10.5% and 29.4 ± 15.0%; and for 1 mg ml À 1 anti-IgM þ 10 mg ml À 1 CD40l 89.6 ± 3.7% and 65.9 ± 8.7%. c.p.m., count per minute.
In vitro cell stimulation assays
Goat anti-IgM F(ab')2 (Jackson Immunoresearch Laboratories, West Grove, PA, USA), anti-CD40 (Clone 1C10), anti-TCR (Clone H57-597), bacterial DNA (CpG; Geneworks, Thebarton, SA, Australia) and LPS, from Escherichia coli (Sigma) were used as agonist for stimulation. All cell stimulations were done in RPMI supplemented with 10% fetal calf serum, 50 U ml À 1 penicillin/streptomycin, 10 mM HEPES, 10 mM sodium pyruvate, 10 mM non-essential minimum essential medium and 55 mM b-mercaptoethanol. For DNA synthesis assay, 2 Â 10 6 cells were cultured for 48 h in 96-well flat bottom plates, before pulsing with 1 mCi [ 3 H]thymidine for 8 h. Intracellular calcium was measured on an LSR flow cytometer (BD Biosciences) following labelling with Indo-1 (Molecular Probes, Eugene, OR, USA). For labelling with CFSE, cells were diluted to a concentration of 20 Â 10 6 cells per ml in phosphate-buffered saline and stained with a final concentration of 2.5 mM CFSE at 37 1C for 10 min. Following two wash with cold RPMI, 2 Â 10 6 cells were cultured for 48 h in 96-well flat bottom plates with appropriate agonist for 5 days.
Western blotting
For B-cell purifications, red-cell-depleted splenocytes were incubated with biotinylated antibodies to CD43 (BD) and B cells were negatively selected using strepavidin MACS bead separation (Miltenyi Biotech, Macquarie Park, NSW, Australia). Cell lysates were subjected to SDS-polyacrylamide gel electrophoresis with a 12.5% gel using the Bio-Rad Mini-Protean II system (Bio-Rad, Hercules, CA, USA). Nitrocellulose membranes (Trans-blot Bio-Rad) and the Bio-Rad Mini-Protean II system was used for transfer according to the manufacturer's instructions. Western blotting using the following antibodies: donkey anti-rabbit IgG F(ab')2-peroxidase (GE Healthcare, Copenhagen, Denmark), goat anti-mouse IgG F(ab')2-peroxidase (GE Healthcare), mouse anti-b-actin monoclonal antibody (Sigma), rabbit anti-PKC-b 1 polyclonal antibody (Sapphire Biosciences, Waterloo, NSW, Australia and Cell Signalling, Genesearch PTY Ltd, Arundel, QLD, Australia), rabbit anti-PKC-b 2 phosphorylated at T642 polyclonal antibody (Sapphire Biosciences) and rabbit anti-PKC-b 2 polyclonal antibody (Sapphire Biosciences and Cell Signalling). Blots were developed using the Western Lightning Western Blot Chemiluminescence Reagent (Perkin Elmer, Waltham, MA, USA).
Bioinformatics
The following bioinformatic tools were used: Boxshade 3. 
Statistical analysis
Data were analyzed using the one-way analysis of variance and Bonfferonni post-test to compare pairs of columns unless otherwise stated, using the GraphPad prism software. Results were considered significant if Po0.05.
